dr. ellis on potential impact of cdk4/6 inhibitors in breast cancer
Published 7 years ago • 105 plays • Length 2:05Download video MP4
Download video MP3
Similar videos
-
1:24
dr. ellis on adjuvant cdk4/6 inhibition in hr-positive breast cancer
-
1:39
dr. ellis on abemaciclib in hr-positive breast cancer
-
1:52
dr. ellis on resistance to endocrine therapy in hr metastatic breast cancer
-
2:06
unmet needs and cdk4/6 inhibitors in hr /her2- early breast cancer
-
3:14
tff1 and tff3 predict response to cdk4/6 inhibitors in breast cancer patients
-
0:50
investigating mechanisms of resistance to cdk4/6 inhibitors
-
4:52
future directions: cdk4/6 inhibitors in breast cancer
-
1:11
dr. accordino on the utility of cdk4/6 inhibitors in hr /her2– breast cancer
-
0:22
copy of dr. ellis on abemaciclib in hr-positive breast cancer
-
1:11
unmet needs in the use of cdk4/6 inhibitors in early-stage hr /her2- breast cancer
-
3:33
cdk 4/6 inhibitors in metastatic breast cancer
-
1:02:43
realizing the potential of cdk 4/6 inhibitor therapy in breast cancer: real-world data and evidence
-
1:08
overcoming resistance to cdk4/6 inhibitors in er breast cancer via ctdna
-
3:21
benefits and challenges of cdk4/6 inhibitors
-
1:17
dr. o’regan on the utility of cdk4/6 inhibitors in breast cancer
-
1:51
reflecting on the use of cdk4/6 inhibitors in hr breast cancer
-
4:35
hr breast cancer: differences between cdk4/6 inhibitors
-
0:50
dr. ellis on immunotherapy in her2 breast cancer
-
4:50
expert report on tackling resistance to cdk4/6 inhibitors in er /her2-metastatic breast cancer